血清总唾液酸和脂结合唾液酸测定对口腔颌面部恶性肿瘤的诊断意义

目的 探讨血清总唾液酸（ＴＳＡ）和脂结合唾液酸（ＬＳＡ）含量对口腔颌面部恶性肿瘤的诊断意义。方法 采用化学比色法同步检测了口腔颌面部恶性肿瘤患者ＴＳＡ和ＬＳＡ含量,并与健康对照组和口腔颌面部良性肿瘤组进行了对比分析。结果 口腔颌面部恶性肿瘤组血清ＴＳＡ和ＬＳＡ含量均明显高于健康对照组和良性肿瘤组（Ｐ〈０．０１）,而健康对照组与良性肿瘤组之间血清ＴＳＡ和ＬＳＡ均无统计学意义（Ｐ〉０．０５）。结论 血     

口腔颌面部肿瘤患者血清CEA测定结果的初步观察

本文介绍通过采用ＥＬＬＩＳＡ法对６１份正常人血清及４９份口腔颌面部肿瘤患者血清进行癌胚抗原（ＣＥＡ）含量测定，得出各组ＣＥＡ含量结果（ｕｇ／Ｌ）。经统计学处理，正常人组（Ｘ±ＳＤ，２．９４±１．５５）与良性肿瘤组（Ｘ±ＳＤ，４．１２±２．００）对比，Ｐ＜０．０１。正常人组与恶性肿瘤组（Ｘ±ＳＤ，５．７５±２．７７）对比，Ｐ＜０．０１。良性肿瘤组与恶性肿瘤组对比，Ｐ＜０．０５．血清ＣＥＡ含量测定阳性率：良性肿瘤组为４．８％，恶性肿瘤组为２５％。由此可以推测口腔颌面部恶性肿瘤患者血清ＣＥＡ含量明显高于正常人和良性肿瘤患者。本文实验结果提示，在口腔科临床开展血清ＣＥＡ含量的测定，对诊断颌面部恶性肿瘤具有一定的辅助作用。     

口腔颌面肿瘤患者血清唾液酸的测定

本文对３８例正常人及２９例口腔颌面部肿瘤患者血清唾液酸水平进行了分析,结果显示：口腔颌面部肿瘤患者血清唾液酸的含量明显高于正常人（ｐ＜０．０１）,且涎腺混合瘤（临界瘤）、口腔颌面部恶性肿瘤患者血清唾液酸的含量均有显著升高（ｐ＜０．０１）,但这两组之间无明显差异（ｐ＞０．０５）．肿瘤血清唾液酸检测的阳性率约为８３％,提示血清唾液酸的升高可作为口腔颌面部肿瘤诊断的辅助指标之一。     

口腔颌面部肿瘤患者血清可溶性白细胞介素─2受体水平的研究

作者用双抗体夹心法酶联免疫吸附试验（ＥＬＩＳＡ法）检测了４６例颌面部肿瘤患者血清可溶性白细胞介素－２受体（ＳＩＬ－２Ｒ）水平、并与２５例正常健康人进行对照比较。结果显示：口腔颌面部恶性肿瘤患者血清ＳＩＬ－２Ｒ水平显著高于颌面部良性肿瘤患者血清ＳＩＬ－２Ｒ水平（Ｐ＜０．０ｌ）及正常健康人血清ＳＩＬ－２Ｒ水平（Ｐ＜０．０ｌ），而颌面部良性肿瘤患者血清ＳＩＬ－２Ｒ水平与正常健康人血清ＳＩＬ－２Ｒ水平之间无显著性差异（Ｐ＞０．０５）。本研究表明、血清ＳＩＬ－２Ｒ有可能作为颌面部恶性肿瘤的诊断、疗效考核及预后判断的一个辅助监测指标。     

ＦＳＧＦ在口腔颌面部肿瘤的检测及其临床意义

目的：研究恶性肿瘤特异生长因子（Ｔumor Specific Growth Factor,TSGF)在口腔颌面面部肿瘤检测。结果：恶性肿瘤组ＴＳＧＦ水平高于正常对照组和良性肿瘤组（Ｐ＜０．０１）,在恶性肿瘤组中第三期ＴＳＧＦ值最高恶性肿瘤组阳率达达７７．７８％。结论：血清ＴＳＧＦ检测对口腔颌面部肿瘤的诊断和预后判断有一定意义,可作为一种有价值的肿瘤标记物应用于临床。     

口腔颌面部肿瘤病者血清SIL-2R水平的临床价值

本文对１９例口腔颌面部良性肿瘤，２２例恶性肿瘤（术前和术后２周），８例复发性恶性肿瘤，１８例无复发恶性肿瘤和２０名正常健康人作血清可溶性白细胞介素－２受体检测．结果良性肿瘤组和无复发组与正常人无显著性差异（ｐ＜０．０５），恶性肿瘤术前和术后２周以及复发组与正常人或良性肿瘤组有非常显著性差异（ｐ＜０．０１）．表明ＳＩＬ－２Ｒ水平检测在临床上对口腔颌面部肿瘤的诊断，治疗过程免疫功能监测和病者预后估测均有较高价值．     

口腔颌面部肿瘤患者血清可溶性白细胞介素—2受体水平的研究

作者用双抗体夹心法酶联免疫吸附试验（ＥＬＩＳＡ法）检测了４６例颌面部肿瘤患者血清可溶性白细胞介素－２受体（ＳＩＬ－２Ｒ）水平，并与２５例正常健康人进行对照比较，结果显示，口腔颌面部恶性肿瘤患者血清ＳＩＬ－２Ｒ水平显著高于颌面部良性肿瘤患者血清ＳＩＬ－２Ｒ水平（Ｐ〈０．０１）及正常健康人血清ＳＩＬ－２Ｒ水平（Ｐ〈０．０１），而颌面部良性肿瘤患者血清ＳＩＬ－２Ｒ水平与正常健康人血清ＳＩＬ－２Ｒ水平之间     

口腔癌患者唾液中肿瘤相关抗原CA—50临床意义的初步探讨

来用免疫放射分析法测定了７０例口腔恶性肿瘤和４０例口腔良性肿瘤患者唾液中ＣＡ－５０抗原，并与７０例正常人作对照，同时还对恶性肿瘤组中６０例作血清ＣＡ－５０测定．结果：恶性肿瘤组中唾液ＣＡ－５０值明显高于正常人组（Ｐ＜０．００１）和良性肿瘤组（Ｐ＜０．０１）．６０例恶性肿瘤组血清ＣＡ５０值仅见３例升高．提出唾液中ＣＡ—５０检测对口腔癌的诊断较血清敏感．     

口腔颌面部肿瘤患者T淋巴细胞亚群及细胞因子检测的临床意义

本文对４０例口腔颌面部恶性肿瘤及２０例良性肿瘤患者同时进行外周血Ｔ淋巴细胞亚群、ｓＩＬ－２Ｒ及ＴＮＦ三项指标检测，结果表明，１．良性、恶性患者均有ＣＤ３值明显下降（Ｐ＜０．０５、ｐ＜０．０ｌ），ｃＤ４／ＣＤ８比值明显下降（ｐ＜０．００ｌ），ＣＤ８值明显上升（Ｐ＜０．００１），并且良性高于恶性患者（ｐ＜０．０５），ｃＤ４值恶性患者有下降趋势（ｐ＞０．０５）。２．恶性患者ｓＩＬ－２Ｒ水平明显高于正常人（ｐ＜０．０１），也高于良性患者（ｐ＜０。０５）。３．ＴＮＦ水平三组尚无明显差异（Ｐ＞０。０５）。４．三项检验指标与恶性肿瘤临床分期有一定相关趋势。提示：Ｔ淋巴细胞亚群、ｓＩＬ－２Ｒ检测对口腔颌面部恶性肿瘤诊断及预后判断具有一定参考价值，ＴＮＦ检测的临床意义尚须进一步研究。     

口腔颌面部肿瘤患者外周血淋巴细胞微核的测定

采用直接离心涂片法对４０例口腔颌面部肿瘤患者和１０名健康人的外周血淋巴细胞微核率进行测定。肿瘤患者微核率（‰）为７．６８±２．７０，其中恶性肿瘤组为８．６８±２．３６，良性肿瘤组为５．３３±１．９２；健康人为１．６０±０，９７。经统计学处理，肿瘤组与对照组，恶性肿瘤与良性肿瘤，恶性肿瘤与对照组，良性肿瘤与对照组之间淋巴细胞微核率均有显著性差异（Ｐ＜０．０１）。提示肿瘤患者染色体畸变明显高于健康人，恶性肿瘤患者染色体畸变又明显高于良性肿瘤患者。     

Serum sialic acid levels in patients with oral and maxillofacial malignancy

Serum sialic acid levels were measured using the thiobarbituric acid method in 80 healthy subjects and in 40 patients with benign and 61 with malignant tumors in the oral and maxillofacial region. It was shown that the cancer group had statistically higher sialic acid levels than control group and the group with benign disease (P less than .05), but no significant difference was noted between the normal control group and the patients with benign tumor (P greater than .05). Serum sialic acid levels were significantly higher in the patients with stages III and IV cancer than in those individuals with stage I and II cancer, but no differences were seen between stages I and II, and between stages III and IV cancer patients (P greater than .05). There was also no difference when considering the anatomic site of the malignant lesion. Furthermore, during the serial sialic acid determination in cancer patients before and following treatment, the sialic acid levels usually declined with remission of the disease and increased with recurrence, metastasis, or a poor prognosis. We conclude from this study that the sequential measurement of sialic acid level is particularly useful in monitoring patients with oral cancer, and sialic acid may prove to be a valuable tumor marker in oral and maxillofacial malignancy.     

67镓显像在口腔颌面部良恶性肿瘤鉴别诊断中的应用价值

目的　研究67镓显像在口腔颌面部良恶性肿瘤鉴别诊断中的应用价值。方法　 41例口腔颌面部肿瘤患者术前行67镓局部显像 ,术后病理检查结果与之对照。结果　恶性肿瘤 2 1例中67镓显像阳性 2 0例 ,阳性率 95 .2 3% ;良性肿瘤 2 0例 ,阳性 3例 ,占 15 .0 0 %。两者差异有高度显著性(P <0 .0 0 1)。结论　67镓显像是一种鉴别口腔颌面部良恶性肿瘤的好方法     

PAⅠ-1 蛋白水平在口腔颌面部肿瘤中的研究

目的：了解口腔颌面部肿瘤组织中Ⅰ型纤溶酶原激活剂抑制剂（ｐａｌｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ－１,ＰＡⅠ－１）蛋白表达情况,分析其与各病理参数间的关系。方法：Ｅ要用发色底物法、ＥＬＩＳＡ夹心法测定３０例口腔颌面部恶性肿组织、相应瘤旁组织及１０例良性肿瘤组织的ＰＡⅠ－１活性及含量。结果：恶性肿瘤组织ＰＡⅠ－１活性及含量明显高于良性肿瘤及瘤旁组织（Ｐ〈０．０１）;ＰＡⅠ－１在     

@^67镓显像在口腔颌面部良恶性肿瘤鉴别诊断中应用价值

目的 研究＾６７镓显像在口腔颌面部良恶性肿瘤鉴别诊断中的应用价值。方法 ４１例口腔颌面部肿瘤患者术前行＾６７镓局部显像，术后病理检查结果与之对照。结果 恶性肿瘤２１例中＾６７镓显像阳性２０例，阳性率９５．２３％；良性肿瘤２０便，阳性３例，占１５．００％。两者差异有高度显著性（Ｐ〈０．００１）。结论 ＾６７镓显像是一种鉴别口腔颌面部良恶性肿瘤的好方法。     

唾液中唾液酸、癌胚抗原测定在口腔鳞癌诊断中的意义

目的 探讨唾液中癌胚抗原(CEA)和唾液酸(SA)含量在口腔颌面部鳞癌诊断中的意义。方法 分别采用酶联免疫吸附(ELLISA)法检测22例口腔鳞癌、22例口腔良性肿瘤患者、40例正常人的CEA和SA含量。结果 SA含量在正常人组与良性肿瘤组间、良性肿瘤与鳞癌组间差异无显著性(P>0.05);正常人组低于鳞癌组(P<0.01)。CEA含量在正常人组低于良性肿瘤和鳞癌组(P<0.01);在鳞癌和良性肿瘤组间差异无显著性(P>0.05)。结论 开展唾液CEA和SA的测定,对诊断颌面部鳞癌具有一定的参考价值。     

口腔颌面部肿瘤患者T淋巴细胞核仁组成区嗜银蛋白的表达

目的　探讨口腔颌面部肿瘤患者外周血T淋巴细胞核仁组成区嗜银蛋白(Ag-NORs)的表达特点及其在口腔颌面部肿瘤诊断中的价值。方法　采用KL型肿瘤免疫图像分析系统及配套试剂,对86例正常人、102例口腔颌面部良性肿瘤和87例恶性肿瘤患者的外周血T淋巴细胞Ag-NORs进行检测,计算银染核仁面积与细胞核面积的比值(I.S%),然后进行综合分析。结果　口腔颌面部良性肿瘤组患者Ag-NORs表达与正常人组相比明显降低,良性肿瘤组平均I.S%值为(5·72±0·14),正常人组平均I.S%值为(7·87±0·12),两组间有显著性差异(P<0·01);恶性肿瘤组患者Ag-NORs表达降低更为明显,平均I·S%值为(4·19±0·13),与正常人组间有显著性差异(P<0·01);良性肿瘤患者组与恶性肿瘤组之间平均I.S%值也有显著性差异(P<0·01)。结论　外周血T淋巴细胞Ag-NORs表达与口腔颌面部肿瘤呈良好的相关性; Ag-NORs的检测可作为口腔颌面部肿瘤诊断及鉴别诊断的一项重要参考指标。     

TSGF在口腔颌面部肿瘤中的检测及其临床意义

目的　研究恶性肿瘤特异生长因子 (TumorSpecificGrowthFactor ,TSGF)在口腔颌面部肿瘤检测中的意义。方法　对 73例口腔颌面部肿瘤患者 (良性 37例 ,恶性 36例 )和 41例正常人血清进行了TSGF检测。结果　恶性肿瘤组TSGF水平高于正常对照组和良性肿瘤组 (P <0 .0 1)。在恶性肿瘤组中第三期TSGF值最高。恶性肿瘤组阳性率达到 77.78%。结论　血清TSGF检测对口腔颌面部肿瘤的诊断和预后判断有一定意义 ,可作为一种有价值的肿瘤标记物应用于临床     

Central skull base invasion of maxillofacial tumors: computed tomography appearance

OBJECTIVE: The aim of this study was to demonstrate computed tomography (CT) features of maxillofacial tumors invading the central skull base and to offer information in aiding diagnosis. METHODS: Fifty-eight maxillofacial tumors with central skull base invasion shown on axial and coronal CT images were divided into benign (13 cases) and malignant (45 cases) groups, based on their pathologic outcomes as proven by biopsy and surgery. RESULTS: Four manifestations of the skull base abnormality were observed on CT images: (1) resorption of central skull base (53 cases, 11 benign and 42 malignant tumors); (2) enlargement of the foramen and canal in the central skull base (20 cases, 4 benign and 16 malignant tumors); (3) thinning of the central skull base (11 cases, 8 benign and 3 malignant tumors); and (4) displacement of the central skull base (5 cases, all benign tumors). The following structures of the central skull base were involved: the roof of the pterygoid process of the sphenoid bone (49 cases), the sphenoid greater wing (37 cases), the sphenoid body and sinus (33 cases), the petrous apex (12 cases), the clivus (4 cases), and the articular surface of the temporal squama (3 cases). Of 58 patients, 30 (7 benign and 23 malignant) had tumors with central skull base erosion that infiltrated into the cranial cavity. CONCLUSION: Benign maxillofacial tumors with center skull base erosion tended to lead to the displacement and thinning of the base of the middle skull fossa in contrast with tumors with malignant maxillofacial tumors. It is believed that these CT manifestations might be valuable in making a differential diagnosis.     

Clinical significance of total and lipid bound sialic acid levels in oral pre-cancerous conditions and oral cancer

BACKGROUND: Altered glycosylation of glycoconjugates is among the important molecular changes that accompany malignant transformation. The purpose of our study was to investigate clinical usefulness of circulatory levels of total and lipid bound sialic acid for early diagnosis and management of oral cavity cancer patients. METHODS: Blood samples were collected from 41 untreated oral cancer patients, 20 patients with oral pre-cancerous conditions (OPC) and 20 healthy subjects. Serum sialic acid (total and lipid bound) levels were measured spectrophotometrically. RESULTS: Serum levels of total and lipid bound sialic acid were significantly elevated (P < 0.001) in untreated oral cancer patients as compared to healthy individuals as well as patients with OPC. Multivariate analysis documented that the progressive rise in total and lipid bound sialic acid was significantly associated (P = 0.0001 and 0.039, respectively) with stage of malignant disease. CONCLUSION: The data revealed significant elevations in sialic acid levels in oral cancer patients and suggested potential utility of these parameters in diagnosis as well as determining clinical stage of the malignant disease.     

Value of gallium-67 scanning in differentiation of malignant tumors from benign tumors or inflammatory disease in the oral and maxillofacial region

OBJECTIVE: The purpose of this study was to evaluate the efficacy of gallium-67 ((67)Ga) scanning in the differentiation of malignant tumors from benign tumors or inflammatory disease in the oral and maxillofacial region.Study design Fifty-two patients with tumors or inflammation in the oral and maxillofacial region underwent (67)Ga scanning. The results were compared with the final pathologic diagnosis. RESULTS: The gallium-67 scanning images for 20 of 21 patients who had malignant tumors were positive (95.23%); images for 3 out of 20 patients who had benign tumors also were positive (15%). There was a significant difference between malignant and benign tumors (P <.001). Images for 2 of 11 patients with chronic inflammatory lesions were positive (18.2%), but, unlike the images of malignant tumors, the image outlines of the inflammatory lesions were indistinct and larger than the actual lesions. CONCLUSION: (67)Ga scanning is a useful adjunct tool for differentiation of malignant tumors from benign tumors or inflammatory disease in the oral and maxillofacial region.